Glycine transporters (GlyTs) are members of the Na + /Cl --dependent neurotransmitter transporter superfamily 9, 10 , integral membrane proteins that use electrochemical gradients to control the concentration of neurotransmitters at central synapses. This superfamily also includes transporters for GABA, biogenic amines (norepinephrine, dopamine, serotonin and proline), betaine, taurine and creatine. GlyTs have dual functions at both inhibitory and excitatory synapses, resulting from the differential localization of two distinct transporters 9, 10 , GlyT1 and GlyT2. GlyT1 is predominantly expressed in glial cells 9, 10 and shows a stoichiometry of 2 Na + /1 Cl -/1 glycine and bidirectional glycine transport 11 . These properties are appropriate for the control of extracellular glycine concentrations in the submicromolar range for modulation of N-methyl-D-aspartate receptors 12 and also for lowering extracellular glycine levels at inhibitory glycinergic synapses 13, 14 . By contrast, GlyT2 is found in glycinergic axons, shows a stoichiometry of 3 Na + /1 Cl -/1 glycine and does not show reverse uptake 11 , reflecting an essential role for GlyT2 in maintaining a high presynaptic pool of neurotransmitter at glycinergic synapses 15 . Na + /Cl --dependent transporters are known targets for therapeutic drugs (for example, anticonvulsants 16 and selective serotonin reuptake inhibitors 17 ) and for drugs of abuse (for example, cocaine and amphetamine). For this reason, genetic variation in human transporter genes has been studied in a variety of disorders including Parkinson disease 18 , depression 18 , orthostatic intolerance 19 and epilepsy 20 . Although mutations in the human creatine transporter gene (SLC6A8) on chromosome Xq28 are associated with mental retardation 21, 22 , no genetic defects in classical Na + /Cl --dependent neurotransmitter transporters (GABA, serotonin and glycine) have been directly related to human disorders. Nevertheless, we considered that neurological disorders with a postsynaptic genetic component might also have a corresponding undiscovered presynaptic defect. For example, hereditary hyperekplexia (OMIM 149400) is a rare but potentially lethal condition, typically caused by mutations in the gene encoding the glycine receptor (GlyR) a1 subunit (GLRA1) [1] [2] [3] . Despite isolated hyperekplexia cases with mutations affecting the GlyR b subunit (GLRB) 4 and the clustering proteins gephyrin (GPHN) 5 and collybistin (ARHGEF9) 6 , for many individuals with sporadic hyperekplexia no causative mutation has been identified [2] [3] [4] [5] [6] [7] . Because knockout mice for the presynaptic Na + /Cl --dependent transporter GlyT2 have been reported 15 to show a phenotype similar to hyperekplexia, as part of a continuing screening program we assessed whether defects in SLC6A5, encoding human GlyT2, could cause this disorder.
We scanned all 16 coding exons of SLC6A5 (11p15.1) by denaturing high-performance liquid chromatography (dHPLC) (for primers see Supplementary Table 1 online) in an international cohort of 83 individuals with sporadic or familial hyperekplexia 2-7 devoid of mutations in GLRA1, GLRB, GPHN and ARHGEF9 (Supplementary Table 2 online). Direct sequencing of aberrant dHPLC profiles revealed a mosaic of missense and nonsense mutations in SLC6A5 ( Table 1 , Fig. 1 and Supplementary Fig. 1 online) and further regions of common SNPs (Supplementary Table 3 online). All mutations in Table 1 were absent from 400 unrelated, normal control chromosomes. In most cases (five of six), SLC6A5 mutations were inherited as compound heterozygotes or as homozygotes, indicating that SLC6A5 is predominantly associated with recessive hyperekplexia (Table 1 and Fig. 1) . A nonsense mutation (resulting in the alteration Y377X) plus a mixed missense and frameshift mutation (resulting in the alteration V432F+fs97) were present in individual 1, who is severely affected and with compound inheritance of null alleles. In the mother, the V432F+fs97-causing mutation segregated with a partial form of hyperekplexia, associated with nocturnal myoclonus and a nervous . Blue triangles show residues in hGlyT2 that are likely to coordinate Na + ions based on sequence alignments with the bacterial leucine transporter LeuT (ref. 24) . This involves residues in TM1 (Gly206, Ala208, Val209, Asn213), TM6 (Ser477), TM7 (Asn509) and TM8 (Lys574, Asp577, Thr578). However, it is noteworthy that GlyT2 binds three Na + ions, whereas LeuT binds two, suggesting that other residues involved in Na + coordination remain to be identified. Filled black circles indicate residues predicted to be involved in glycine binding, including residues in TM1 (Tyr207, Ala208, Lys211, Gly212), TM3 (Ile283, Tyr287), TM6 (Phe475, Phe476, Ser479, Trp482) and TM8 (Thr578, Thr582). disposition. However, the Y377X-causing paternal allele did not evoke a hyperekplectic phenotype. Compound heterozygosity in individual 2 consisted of nonsense and missense mutations resulting in the substitutions Q630X and Y491C, respectively. The origin of these alleles could not be determined in the unaffected parents because they had declined to participate in this study. However, long-distance PCR from exons 9 and 13 and subsequent cloning of PCR products showed that these alleles resided on different chromosomes. Individual 3 represents two sibling brothers with hyperekplexia; both inherited missense plus frameshift and missense mutations (resulting in the alterations P108L+fs25 and W482R, respectively) from their unaffected parents. Individual 4 inherited two missense mutations resulting in the substitutions L306V and N509S; individual 5 was homozygous for a single missense mutation (resulting in the substitution T425M) inherited from consanguineous parents. Finally, a maternal missense mutation (resulting in the substitution S510R) was identified in individual 6. Although a paternal sequence variation (A89E) was identified, we were able to exclude the possibility of compound heterozygosity because this variant was also detected in 4 of 203 control samples. All individuals with mutations in SLC6A5 presented with classical symptoms of hyperekplexia (see Supplementary Note and Supplementary Video 1 (for individual 6) online), including neonatal muscle hypertonia and an exaggerated startle response to tactile or acoustic stimuli with preservation of consciousness. However, in contrast to most individuals with mutations in GLRA1, individuals with SLC6A5 mutations showed prolonged spasms with life-threatening neonatal apnea and breath-holding episodes. Notably, in some cases, symptoms resolved in the first year of life.
To confirm the pathogenicity of these alleles, we performed a series of functional tests using recombinant expression of human GlyT2 and mutants produced by site-directed mutagenesis. These experiments included assessment of cell-surface localization and capacity for [ 3 H]glycine uptake in HEK293 cells, together with electrophysiological measurements of glycine-evoked steady-state currents in Xenopus laevis oocytes. Non-mutated EGFP-or myc-tagged hGlyT2 as well as A89E, L306V, T425M, W482R, Y491C and N509S mutants were readily expressed at the cell surface (Fig. 2a) . By contrast, frameshift (P108L+fs25 and V432F+fs97) and nonsense (Y377X and Q630X) mutant proteins were clearly cytoplasmic, suggesting that protein truncation resulted in a loss of cell surface GlyT2. The S510R mutant protein was also cytoplasmic, but it formed intracellular aggregates (Fig. 2a,b ) that readily trapped cotransfected myc-tagged hGlyT2 (Fig. 2b) , supporting a dominant-negative mode of action. Consistent with these findings, substitutions P108L+fs25, Y377X, V432F+fs97, Q630X and S510R abolished [ 3 H]glycine uptake (Fig. 3a) . Despite reaching the cell surface, transporters with substitutions T425M, W482R, Y491C and N509S also showed no significant [ 3 H]glycine uptake, whereas those with A89E and L306V resembled EGFP-hGlyT2 (Fig. 3a) . Taken together, these data provide strong evidence for a biallelic loss of GlyT2 function in individuals 1 (Y377X plus V432F+fs97), 2 (Q630X plus Y491C), 3 (P108L+fs25 plus W482R) and 5 (T425M, homozygous). However, the mechanisms underlying the clinical phenotype in individuals 4 (L306V plus N509S) and 6 (heterozygous for S510R) remained ambiguous. We therefore tested whether cotransfection of the two alleles would provide evidence for dominant or synergistic effects, as intracellular heteromeric GlyT2 assembly has been reported, although cell-surface GlyT2 is presumed to be monomeric 23 . Mixing N509S or L306V with EGFP-hGlyT2 did not substantially alter [ 3 H]glycine uptake, but mixing N509S with L306V completely abolished uptake (Fig. 3b) . This indicates that in vivo, N509S and L306V mutant polypeptides may act synergistically to cause biallelic GlyT2 dysfunction, compatible with a recessive mode of inheritance. Consistent with cytoplasmic trapping of myc-tagged GlyT2 by EGFP-hGlyT2S510R (Fig. 2b) , coexpression of S510R with hGlyT2 or A89E resulted in the loss of [ 3 H]glycine uptake (Fig. 3b) , providing further evidence that the mutation producing the S510R substitution is dominant negative.
Insights into the precise molecular mechanisms underlying mutations in SLC6A5 were provided by homology modeling of GlyT2 using the crystal structure of the bacterial leucine transporter (LeuT; ref. 24 us to identify residues potentially involved in coordinating glycine and Na + binding. In particular, we predicted that alterations W482R (TM6) and N509S (TM7) could disrupt the binding to GlyT2 of glycine or Na + , respectively (Fig. 1a-c) .
Two-electrode voltage-clamp analysis in Xenopus oocytes demonstrated that the mutant W482R does not respond to glycine (up to 10 mM). However, the mutant W482R was clearly present at the cell surface, as demonstrated by Na + -dependent transient currents 9, 25 that were glycine insensitive but blocked by the drug ORG25543 (a specific GlyT2 inhibitor; Fig. 4a-c) . By contrast, neither transient nor glycineinduced currents could be detected for mutants T425M, Y491C or S510R. This confirmed our prior [ 3 H]glycine uptake results (Fig. 3a) and indicated that although T425M and Y491C reach the cell surface (Fig. 2a) , they may not be functional. Transient and steady-state currents, which are related to transporter expression 26, 27 , were observed for L306V and for N509S. However, disruption of the highly conserved residue N509 produced a marked and voltage-dependent decrease in glycine potency (Fig. 4b-c ) from a half-maximal effector concentration (EC 50 ) of 26.9 ± 3.3 mM (hGlyT2) to 1,920 ± 230 mM (N509S) at -40 mV (Fig. 4c) . Similar results were obtained for glycine-activated currents for hGlyT2 and N509S expressed in NG108 cells ( Supplementary Fig. 2 online; EC 50 at -50 mV for hGlyT2, 27.4 ± 2.4 mM; for N509S, 2,650 ± 420 mM). These shifts in potency were sufficient to account for the apparent lack of glycine uptake for N509S in HEK293 cells ( Fig. 3a; assayed using 200 mM glycine) and demonstrated that although N509S may impair Na + -glycine coupling, alteration L306V alone did not substantially impair transporter function. Current-voltage relationships for N509S and L306V in oocytes were similar to that for hGlyT2, showing that these mutants conserved a high thermodynamic coupling between glycineevoked current and glycine uptake (Fig. 4d) . We assessed the charge movement (Q v ) across the oocyte membrane associated with the activation of GlyT2 by measuring the integrals of the transient currents at different voltage-clamp holding potentials (V m ). Fitting the resulting Q v -V m relationships to the Boltzmann equation showed that all possessed similar equivalent charges (zd) to hGlyT2, indicating no difference in the number of Na + ions that are bound to the transporter. However, the holding potential at which the charge transfer is half the maximum (V 0.5 ) for all three GlyT2 mutants was shifted to hyperpolarized potentials, in accord with a reduced apparent affinity for Na + (Fig. 4e) .
In conclusion, it is apparent that hyperekplexia is principally caused by defects in glycinergic transmission that conspire to alter either postsynaptic receptor function or location or, alternatively, presynaptic vesicular replenishment. Although mouse knockouts for GlyT2 have been suggested 15 to show a behavioral phenotype similar to human hyperekplexia, there are several marked differences from individuals with mutations in SLC6A5. GlyT2 knockout mice gain weight slowly and die prematurely at the end of the second postnatal week, showing a complex neurological phenotype characterized by spasticity, a severely impaired righting reflex and, of particular note, rigid muscle tone and strong spontaneous tremor. By contrast, humans with mutations in SLC6A5 show no spontaneous tremor or muscle stiffness, although these can be triggered by acoustic or tactile stimuli.
Our results demonstrate that SLC6A5 is a major gene for hyperekplexia and define the first neurological disorder linked to alterations in a Na + /Cl --dependent transporter for a classical fast neurotransmitter. By analogy, we suggest that in other human disorders where defects in postsynaptic receptors have been identified, similar symptoms could result from defects in the cognate presynaptic neurotransmitter transporter. In the hierarchical genetic analysis of hyperekplexia, SLC6A5 must now be regarded as an important candidate gene and have equal priority to GLRA1 in screening. GlyT2 accessory proteins (such as the PDZ-domain-containing protein syntenin-1 and ULIP6) that are involved in the correct localization of GlyT2 at presynaptic terminals 28,29 must also be considered as candidates for the remaining individuals with hyperekplexia awaiting a definitive genetic diagnosis. Finally, although mutations in SLC6A5 should be regarded as a risk factor for sudden infant death syndrome, owing to developmentally specific anoxic seizures and cyanotic syncope, symptoms often resolve during the transient developmental period from early postnatal months into infancy.
METHODS
Mutation screening of the human GlyT2 gene (SLC6A5). We screened 83 samples, all of which had proved gene-negative in screens [3] [4] [5] [6] of GLRA1, GLRB, GPHN and ARHGEF9, for SLC6A5 mutations. Four samples came from two sets of asymptomatic parents of affected children and three others came from members of a large family with one severely affected individual. The remaining 76 samples all came from unrelated individuals with sporadic cases from neurological or genetics clinic referrals. Ethical approval for the genetic testing of individuals with epilepsy and paroxysmal disorders is held with the Auckland Regional Ethical Committee in New Zealand (M.I.R.). The referring clinicians hold written consent from participants or parents for blood sample collection and genetic screening in accordance with individual national ethical requirements. Separate parental consent was obtained to publish Supplementary Video 1. Participant and physician written consent was a study prerequisite, but because of the multinational origin of DNA samples, the consent format was not standardized. We derived SLC6A5 exons, flanking intronic sequences and 5¢ and 3¢ untranslated regions in silico, using the Human Genome Browser at UCSC. We amplified participant genomic DNA using PCR primers described in Supplementary Table 1. Each 25 ml reaction contained 60 ng of genomic DNA, 10 pmol of each primer, 1.5 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl buffer, pH 8.3, 200 mM dNTPs and 1 U Taq polymerase (Qiagen). PCR conditions were 94 1C for 5 min followed by 35 cycles of 30 s at 94 1C, 30 s at 60 1C and 30 s at 72 1C. We screened PCR products for SNPs and other mutations using a dHPLC HT-WAVE DNA Fragment Analysis System with DNASep columns (Transgenomic) under partially denaturing conditions. For samples showing aberrant dHPLC profiles, we isolated the DNA from gels (QIAGEN) and sequenced it using ABI3100 and BigDye ready reaction technology (Applied Biosystems). We screened population samples using RFLPs or, in the absence of a restriction site assay, analyzed dHPLC profiles of controls with a mutation-positive sample.
Amplification, cloning and mutagenesis of human GlyT2 cDNAs. We amplified human GlyT2 cDNAs from human hippocampal cDNA (Clontech) using the primers hGlyT2A-1 and hGlyT2A-2 (Supplementary Table 1 online) and 30 cycles of 94 1C for 1 min, 60 1C for 1 min and 68 1C for 6 min. We cloned PCR products into the EcoRI and XhoI sites of the vector pcDNA3 (Invitrogen) and sequenced 12 full-length cDNAs. hGlyT2-1 encodes Gly102, Ser124, Lys457 and Asp463 (Supplementary Table 3 online) . We subcloned the insert from one of these clones, pcDNA3-hGlyT2-1, into three more vectors: pEGFP-C1 (Clontech; resulting in construct pEGFP-hGlyT2, N-terminal EGFP tag), pRK5myc (resulting in construct pRK5myc-GlyT2, N-terminal myc tag) and pRC/CMV (Invitrogen; resulting in plasmid pRC/CMV-hGlyT2). Then we introduced SLC6A5 mutations into these plasmids using the QuikChange site-directed mutagenesis kit (Stratagene). We sequenced the full coding region of each construct as above to verify that only the desired mutation had been introduced.
Glycine uptake assays. We plated HEK293 cells (ATCC CRL1573) onto poly-D-lysine-coated 24-well plates (Nunc) and grew them to 50% confluence in MEM (Earles salts) supplemented with 10% (vol/vol) FCS, 2 mM L-glutamine and 20 U/ml penicillin-streptomycin in 5% CO 2 -95% air. We transfected them with 0.25 mg total pEGFP-C1 (control), pEGFP-hGlyT2 or mutant DNAs per well using Effectene (Qiagen). After 24 h, we washed the cells with a buffer containing 116 mM NaCl, 1 mM NaH 2 PO 4 , 26 mM NaHCO 3 , 1.5 mM MgSO 4 , 5 mM KCl, 1.3 mM CaCl 2 and 5 mM glucose pre-equilibrated with 5% CO 2 -95% air, then incubated them for 5 min in 1 mCi/ml [ 3 H]glycine (60 Ci/mmol, NEN) at a final concentration of 200 mM. Two additions of ice-cold buffer followed by aspiration terminated the uptake. We then digested cells in 0.1 M NaOH and used these samples for scintillation counting and for determination of protein concentration using Bradford reagent (Bio-Rad). 10 min before further washing in PBS. For confocal microscopy we used a Zeiss Axioscop LSM 510 Meta confocal microscope with 40Â objective (NA 1.3) and 3Â digital zoom. We acquired images (1,024Â1,024 pixel resolution) after laser excitation (488 nm) of a 0.9-mm optical section and stored them for further analysis. We transfected each mutant at least four times and obtained images from at least four cells per mutant. Phenotypes shown were present in 485% of transfected cells. Cells showing extreme levels of exogenous protein expression, obvious cell volume loss or other signs of cell death were discounted from image analysis.
Electrophysiological analysis of GlyT2 mutants. We prepared Xenopus oocytes as previously described 9 . We synthesized mRNAs coding for wild-type GlyT2 and each mutant in vitro from pRC/CMV-hGlyT2 constructs (mMessagemMachine, AMBION) and injected B50 ng of mRNA into each Xenopus oocyte. Three to seven days after mRNA injection, we held the oocyte at -40 mV with a two-microelectrode voltage-clamp amplifier (WARNER OC725C) while continuously perfusing with Ringer's solution (100 mM NaCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 5 mM HEPES buffer, adjusted to pH 7.4 with KOH). We filtered the currents at 1 kHz before digitizing them at 5 kHz (Digidata 1200 or 1320A, Axon Instruments, PClamp 8).
We grew NG108-15 cells under nondifferentiating conditions in MEM (Earles salts) with 10% (vol/vol) FCS, 4 mM L-glutamine, 1.13% (wt/vol) glucose, 20 U/ml penicillin-streptomycin and 2% HAT media supplement (50Â) in 5% CO 2 -95% air. We plated cells onto polyornithine-coated coverslips and transfected them with cDNAs for GlyT2 and EGFP using calcium phosphate. Up to 16 h later (at 20-22 1C), we recorded whole-cell glycineevoked currents, normalized to cell capacitance, from single NG108 cells voltage clamped at -50 mV using an Axopatch 200B (Axon Instruments) and filtered the currents (8-pole Bessel) at 2 kHz before digitizing them (Digidata 1320A). Patch electrodes (3-5 MO) contained 140 mM potassium gluconate, 1 mM MgCl 2 , 1 mM CaCl 2 , 11 mM EGTA, 5 mM ATP and 10 mM HEPES, pH 7.2. Krebs solution for continuous superfusion contained 140 mM NaCl, 4.7 mM KCl, 1.2 mM MgCl 2 , 2.5 mM CaCl 2 , 11 mM glucose and 10 mM HEPES, pH 7.4. We applied all solutions using a modified U-tube. We analyzed the data using Clampfit 8.2 (Axon) and Origin 6 (Microcal). Dose-response relationships we fitted with the Hill equation. All data points represent the mean ± s.e.m.
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